Evidence map›Paper›PMID 40570172›Full record

ArticleThe Biochemical journal2025

Structure and activity of the essential UCH family deubiquitinase DUB16 from Leishmania donovani.

James A Brannigan, Mohd Kamran, Nathaniel G Jones, Elisa M Nightingale, Eleanor J Dodson, Sarfaraz A Ejazi, Jeremy C Mottram, Nahid Ali, Anthony J Wilkinson

Abstract read
In one paragraph

Article in The Biochemical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Novel Chalcone Derivatives as Anti-Antibiotics (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

James A Brannigan *York Structural Biology Laboratory, Department of Chemistry, York Biomedical Research Institute, University of York, York, YO10 5DD, U.K.ORCID 0000-0001-6597-8972
Mohd Kamran *Infectious Diseases and Immunology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, West Bengal, 700032, India.ORCID 0000-0001-9007-6735
Nathaniel G JonesYork Biomedical Research Institute and Department of Biology, University of York, York, YO10 5DD, U.K.ORCID 0000-0001-7328-4487
Elisa M NightingaleYork Structural Biology Laboratory, Department of Chemistry, York Biomedical Research Institute, University of York, York, YO10 5DD, U.K.ORCID 0000-0001-9219-4196
Eleanor J DodsonYork Structural Biology Laboratory, Department of Chemistry, York Biomedical Research Institute, University of York, York, YO10 5DD, U.K.ORCID 0000-0002-8968-9814
Sarfaraz A EjaziInfectious Diseases and Immunology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, West Bengal, 700032, India.ORCID 0000-0001-7312-1549
Jeremy C MottramYork Biomedical Research Institute and Department of Biology, University of York, York, YO10 5DD, U.K.ORCID 0000-0001-5574-3766
Nahid AliInfectious Diseases and Immunology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, West Bengal, 700032, India.ORCID 0000-0002-6166-3778
Anthony J WilkinsonYork Structural Biology Laboratory, Department of Chemistry, York Biomedical Research Institute, University of York, York, YO10 5DD, U.K.ORCID 0000-0003-4577-9479

Funding

Wellcome Trust
6 · The paper itself

Abstract

In Leishmania parasites, as for their hosts, the ubiquitin (Ub) proteasome system is important for cell viability. As part of a systematic gene deletion study, it was discovered that four cysteine protease-type deubiquitinases (DUBs) are essential for parasite survival in the promastigote stage, including DUB16. Here, we have purified and characterised recombinant DUB16 from Leishmania donovani, which belongs to the Ub C-terminal hydrolase (UCH) family. DUB16 efficiently hydrolyses C-terminal aminocoumarin and rhodamine conjugates of Ub consistent with proposed cellular roles of UCH-type DUBs in regenerating free monomeric Ub from small molecule Ub adducts arising from adventitious metabolic processes. The crystal structure of DUB16 reveals a typical UCH-type DUB fold, and a relatively short and disordered cross-over loop that appears to restrict access to the catalytic cysteine. At close to stoichiometric enzyme to substrate ratios, DUB16 exhibits DUB activity towards diubiquitins linked through isopeptide bonds between Lys11, Lys48 or Lys63 residues of the proximal Ub and the C-terminus of the distal Ub. With 100-1000-fold higher turnover rates, DUB16 cleaves the ubiquitin-ribosomal L40 fusion protein to give the mature products. A DUB-targeting cysteine-reactive cyanopyrrolidine compound, IMP-1710, inhibits DUB16 activity. IMP-1710 was shown in promastigote cell viability assays to have parasite killing activity with EC50 values of 1-2 μM, comparable with the anti-leishmanial drug, miltefosine. L. mexicana parasites engineered to overproduce DUB16 showed a modest increase in resistance to IMP-1710, providing evidence that IMP-1710 inhibits DUB16 in vivo. While it is highly likely that IMP-1710 has additional targets, these results suggest that DUB16 is a potential target for the development of new anti-leishmanial compounds.

Indexed as

Deubiquitinating EnzymesLeishmania donovaniProtozoan ProteinsCrystallography, X-RaySubstrate SpecificityUbiquitinDeubiquitinating EnzymesProtozoan ProteinsUbiquitincrystal structuredeubiquitinaseleishmaniasubstrate specificityUCH family

Identifiers

PMID40570172
PMCPMC12409989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.